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Abstract 
New initiatives have been introduced in Europe and the USA to encourage more rapid development of antibiotics. The need to 
ensure these new antibiotics can be safely used in children, and especially neonates, is important owing to high antimicrobial 
resistance in these patient groups. This review aims to determine what lessons can be learnt from the recent regulatory 
processes to speed up access to new medicines for children, focusing on antibiotics licensed for adults by the EMA since 2000. 
For the 11 newly approved antibiotics, 31 clinical trials enrolling children in Europe were identified. However, many of these 
trials included both adults and children but did not provide a subset analysis for paediatrics, limiting the relevance of their 
findings. Some studies have been prematurely terminated and others are apparently active but are still not yet recruiting 
patients. Among paediatric-specific studies, 18 evaluate safety and efficacy of new compounds, 4 are pharmacokinetic studies, 
but only 2 focus on neonates. Nearly all studies with an agreed Paediatric Investigation Plan have just started or are not yet 
recruiting. For most antibiotics, despite adult phase 3 studies being completed, with specific concerns for particular drugs 
already noted, it will take another 3–5 years before adequate prescribing information becomes available for paediatricians. 
Evidence from this review suggests that we could do better. Lessons should be learnt from paediatric antiretroviral 
development, with neonatal and paediatric pharmacokinetic, clinical trial and pharmacovigilance drug development 
programmes being run directly in parallel with adult studies—not a decade behind. 
 
1. Introduction 
The development of novel antibiotics is a key priority of antibacterial therapy in the 21st century. The US Food and Drug 
Administration (FDA) in the USA and the European Medicines Agency (EMA) in Europe are responsible for the scientific 
evaluation of applications for marketing authorisation of medicinal products and for the approval of specific proposed clinical 
indications for each compound. 
Appropriate use of antibiotic agents may minimise selective pressure on the emergence of drug-resistant strains [1] and [2]. 
The licensing and marketing of a drug occur at the end of a long development process, in which clinical trials represent the 
final critical stage [3]. 
In the paediatric setting, the number of clinical trials is very low compared with the adult population: both economic and 
ethical factors can discourage pharmaceutical companies in conducting trials on children [4]. The result is a potential delay in 
the authorisation of antibiotics for children and a consequent increase in off-label prescribing [5]. Moreover, given the paucity 
of information of new antibiotics in children, data on drug safety and tolerability are often extrapolated from adult studies, with 
the consequent risks of underestimating toxicity, inadequate dosages and clinical failures [6]. 
Important new initiatives have recently been introduced both in the USA and Europe to encourage earlier and more complete 
evaluation of new drug products in paediatrics. The ‘Paediatric Regulation’ is a new legislation governing the development and 
authorisation of medicines in children that was introduced in the European Union (EU) in 2007 [7]. It brought in the creation 
of a Paediatric Committee, within the EMA, that provides objective scientific opinions on required drug development plans 
submitted by pharmaceutical companies. Such Paediatric Investigation Plans (PIPs) are aimed at ensuring that the necessary 
data to support authorisation of the medicine for paediatric use are obtained through targeted studies [8]. Further initiatives are 
now proposed to enhance the more rapid development of antibiotics. This study therefore aimed to see what lessons can be 
learnt from the recent regulatory processes to speed up access to new medicines for children, focusing on antibiotics licensed 
for adults by the EMA since 2000. 
2. Materials and methods 
The Medline, EMBASE and Cochrane library databases were systematically searched from January 2000 to December 2012 to 
identify all published papers regarding prospective clinical trials on the use of new antibiotics in infants and children aged 0–
17 years and involving European countries. Only new antibiotics that have been licensed in the EU for adult use were 
considered. A cross-check on references of major articles reporting adult data was also performed. To identify ongoing trials or 
recently completed trials, a search of the World Health Organization (WHO), US National Institutes of Health and EU clinical 
trials registers was performed (last accessed 31 January 2013) [9], [10] and [11]. PIPs were systematically searched through 
the EMA database [8]. 
3. Results 
Eleven antibiotics approved in the EU since 2000 were identified (Table 1). A total of 31 clinical trials were found. A brief 
summary of completed and ongoing trials, as well as PIPs, for each drug is given. 
Table 1. 
Antimicrobials licensed for the adult population in the European Union (EU) since 2000. 
Drug EU approved indications in adults 
EU approved indications in 
children 
Paediatric Investigation 
Plans (EU) 
Aztreonam 
lysine 
Pseudomonas aeruginosainfection in 
patients with cystic fibrosis 
None None 
Ceftaroline 
fosamil 
cSSTI, CAP None cSSTIs, CAP (0–18 years) 
Daptomycin cSSTI, Staphylococcus 
aureusbacteraemia, S. aureus right-
sided endocarditis 
None None 
Doripenem 
monohydrate 
cIAI, cUTI, HAP None HAP/VAP, cIAI, UTI (0–
18 years) 
Ertapenem 
sodium 
cIAI, CAP, cSSTI (diabetic foot), acute 
pelvic infection, surgical-site infection 
cIAI, CAP, cSSTI (diabetic 
foot), acute pelvic infection 
None 
Drug EU approved indications in adults 
EU approved indications in 
children 
Paediatric Investigation 
Plans (EU) 
prophylaxis in elective colorectal 
surgery 
in children aged ≥3 months 
of age 
Fidaxomicin CDAD None Safety and 
pharmacokinetics (2–17 
years) 
Development of an age-
appropriate oral suspension 
formulation (0–18 years) 
Linezolid HAP, CAP, cSSTI by Gram-negative 
bacteria 
None None 
Moxifloxacin Acute bacterial sinusitis, AECB, CAP None PID (12–18 years) 
cIAI (3 months to 18 years) 
Retapamulin Superficial SSTI (impetigo, infected 
small lacerations, abrasions or sutured 
wounds) 
Superficial SSTI (impetigo, 
infected small lacerations, 
abrasions or sutured 
wounds) in children ≥9 
months of age 
None 
Telithromycin CAP (mild to moderate) None None 
Tigecycline cSSTI, cIAI None cSSTIs, cIAIs (8–18 years) 
cSSTI, complicated skin and soft-tissue infection; CAP, community-acquired pneumonia; cIAI, complicated intra-abdominal 
infection; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated 
pneumonia; CDAD, Clostridium difficile-associated diarrhoea; AECB, acute exacerbations of chronic bronchitis; PID, pelvic 
inflammatory disease. 
Table options 
3.1. Aztreonam lysine 
Aztreonam is a synthetic monobactam that has been available intravenously for many decades. It displays a mechanism of 
action similar to penicillin and has selective bactericidal activity against susceptible Gram-negative bacteria, 
including Pseudomonas aeruginosa and most clinically relevant Enterobacteriaceae. Aztreonam is inactivated by extended-
spectrum β-lactamases (ESBLs) and has no activity against Gram-positive bacteria or anaerobes. 
An inhaled formulation, aztreonam lysine (AZLI), administered using an ultrasonic nebuliser, was recently developed. It 
received conditional approval by the EMA in 2009 for the treatment of P. aeruginosa infections in adults with cystic fibrosis 
and was also approved by the FDA in 2010, although not in children [12] and [13]. Three clinical trials enrolling children with 
cystic fibrosis and lower respiratory tract infections with P. aeruginosa are registered in Europe ( Table 2). AZLI demonstrated 
superiority in lung function and a reduction in acute pulmonary exacerbations compared with tobramycin inhalation solution in 
adult and paediatric patients with pulmonary P. aeruginosacolonisation. However, only a small number of children were 
enrolled (n = 58; 22%) and no separate analysis for the paediatric population was performed [14] and [15]. Two studies 
evaluating the safety and efficacy of AZLI are active but are not yet recruiting patients [16] and [17]. 
Table 2. 
European clinical trials on aztreonam lysine involving paediatric patients. 
Study no. 
St
ud
y 
ty
pe 
Loca
tions 
No
. 
of 
pts 
Ag
e 
Type of 
infectio
n 
Primary 
endpoin
t 
Secondary 
endpoint 
Main 
exclusion 
criteria 
Comp
arator 
Aztreo
nam 
dose/d
uratio
n 
Statu
s Results 
 
NCT0075723
7[14] and [15] 
Ph
as
e 
3, 
R
C
T, 
O
L 
USA
, 
Euro
pe 
26
8 
(5
8 
ag
ed 
<1
8 
ye
ars
) 
≥6 
yea
rs 
Pulmon
ary 
infectio
n 
by Pseu
domona
s 
aerugin
osa in 
pts with 
CF 
Compar
ative 
safety 
and 
efficacy 
– Previous 
antipseudo
monal 
treatment; 
lung 
transplant
ation; 
colonisati
on 
by Burkho
lderiaspp.; 
continuou
s oxygen 
supplemen
tation; 
high-dose 
steroids 
TNS 
300 
mg 
q12h 
as 
inter
mitte
nt 28-
day 
cours
es 
Inhalat
ion 
solutio
n 
75 mg 
q8h as 
interm
ittent 
28-day 
course
s 
Com
plete
d 
Mean 
relative 
changes 
after one 
course: 
AZLI, 
8.35%; 
TNS, 
0.55% 
(P < 0.0
01). 
Mean 
actual 
changes 
across 
three 
courses: 
AZLI, 
2.05%; 
TNS,–
0.66% 
(P = 0.0
02) 
 
Study no. 
St
ud
y 
ty
pe 
Loca
tions 
No
. 
of 
pts 
Ag
e 
Type of 
infectio
n 
Primary 
endpoin
t 
Secondary 
endpoint 
Main 
exclusion 
criteria 
Comp
arator 
Aztreo
nam 
dose/d
uratio
n 
Statu
s Results 
 
Fewer 
respirato
ry 
hospitali
sations 
(P = 0.0
44) and 
respirato
ry 
events 
requirin
g 
addition
al 
antipseu
domonal 
antibioti
cs 
(P = 0.0
04) in 
AZLI-
treated 
pts 
Study no. 
St
ud
y 
ty
pe 
Loca
tions 
No
. 
of 
pts 
Ag
e 
Type of 
infectio
n 
Primary 
endpoin
t 
Secondary 
endpoint 
Main 
exclusion 
criteria 
Comp
arator 
Aztreo
nam 
dose/d
uratio
n 
Statu
s Results 
 
NCT0137504
9[16] 
Ph
as
e 
2, 
O
L 
USA
, 
Euro
pe 
80 3 
mo
nth
s to 
17 
yea
rs 
Lower 
respirat
ory tract 
infectio
n by P. 
aerugin
osa in 
pts with 
CF 
Microbi
ological 
respons
e 
– Previous 
antipseudo
monal 
treatment; 
lung 
transplant
ation; 
colonisati
on 
by Burkho
lderiaspp.; 
continuou
s oxygen 
supplemen
tation 
None Inhalat
ion 
solutio
n 
75 mg 
q8h 
for 28 
days 
Activ
e but 
not 
recru
iting 
NA  
NCT0140423
4[17] 
Ph
as
e 
3, 
O
L 
USA
, 
Euro
pe 
60 Up 
to 
12 
yea
rs 
Chronic 
lower 
respirat
ory tract 
infectio
n by P. 
aerugin
osa in 
Safety Efficacy: 
improvemen
t of 
respiratory 
functionalit
y and 
changes 
in P. 
Previous 
antipseudo
monal 
treatment; 
lung 
transplant
ation; 
colonisati
None Inhalat
ion 
solutio
n 
75 mg 
q8h as 
three 
interm
Activ
e but 
not 
recru
iting 
NA  
Study no. 
St
ud
y 
ty
pe 
Loca
tions 
No
. 
of 
pts 
Ag
e 
Type of 
infectio
n 
Primary 
endpoin
t 
Secondary 
endpoint 
Main 
exclusion 
criteria 
Comp
arator 
Aztreo
nam 
dose/d
uratio
n 
Statu
s Results 
 
pts with 
CF 
aeruginosae
xacerbations 
and sputum 
density 
on 
by Burkho
lderiaspp. 
ittent 
28-day 
course
s 
pts, patients; RCT, randomised controlled trial; OL, open label; CF, cystic fibrosis; TNS, tobramycin nebuliser solution; q12h, 
every 12 h; q8h, every 8 h; AZLI, aztreonam for inhalation solution; NA, not available. 
Table options 
No PIP is currently agreed on AZLI. 
3.2. Ceftaroline fosamil 
Ceftaroline fosamil is a novel broad-spectrum cephalosporin approved by the EMA in 2012 for the treatment of adults with 
complicated skin and soft-tissue infections (cSSTIs) and community-acquired pneumonia (CAP) [18]. 
Ceftaroline inhibits bacterial cell wall synthesis by binding penicillin-binding proteins (PBPs), including PBP2a produced by 
meticillin-resistant Staphylococcus aureus(MRSA). It has activity against a wide spectrum of Gram-negative and Gram-
positive pathogens, such as MRSA (including vancomycin- and daptomycin-resistant strains), penicillin-
resistant Streptococcus pneumoniae (PRSP), meticillin-resistant Staphylococcus epidermidis (MRSE) and Enterococcus 
faecalis. It is not active against P. aeruginosa and ESBL-producing strains [19]. 
Although clinical data are still limited, ceftaroline displays a good safety and tolerability profile. The paediatric dosage is yet to 
be determined. In addition to the approved indications, a potential promising role for ceftaroline is empirical monotherapy 
when an MRSA or MRSE infection is suspected. 
Two randomised controlled trials (RCTs) are recruiting paediatric patients in Europe (Table 3): they will assess the safety, 
efficacy, tolerability and pharmacokinetics of ceftaroline versus comparators in children aged 2 months to 18 years with CAP 
and cSSTIs [20] and [21]. 
Table 3. 
European clinical trials on ceftaroline fosamil involving paediatric patients. 
Study no. 
Stu
dy 
typ
e 
Locati
ons 
No. of 
pts Age 
Type 
of 
infect
ion 
Primary 
endpoint 
Secondary 
endpoint(s) 
Main 
exclusion 
criteria 
Comparato
r(s) 
Ceftaro
line 
fosamil 
dose Status 
NCT015307
63[20] 
Pha
se 
2–
3, 
RC
T, 
SB 
USA, 
Europ
e 
160 
(estima
ted) 
2 
mon
ths 
to 
18 
year
s 
CAP Compar
ative 
safety 
and 
tolerabil
ity 
Comparativ
e efficacy; 
pharmacoki
netics of 
ceftaroline 
fosamil in 
plasma and 
CSF 
Hypersensi
tivity to β-
lactams; 
infection 
with a 
pathogen 
resistant to 
ceftriaxone
; sources 
of 
infection 
other than 
CAP; non-
infectious 
causes of 
pulmonary 
infiltrates 
Ceftriaxon
e i.v. 
75 mg/kg/d
ay (up to 
4 g/day) 
divided 
q12h 
≥6 
months
: i.v. 
ceftarol
ine 
fosamil 
12 mg/
kg (if 
≤33 kg 
body 
weight) 
or 
400 mg 
(if 
>33 kg 
body 
weight) 
q8h<6 
Recrui
ting 
months
: 
8 mg/k
g q8h 
NCT014008
67[21] 
Pha
se 
2–
3, 
RC
T, 
SB 
USA, 
Europ
e, 
South 
Ameri
ca, 
Asia, 
South 
Africa 
270 
(estima
ted) 
2 
mon
ths 
to 
18 
year
s 
cSST
I 
Compar
ative 
safety 
and 
tolerabil
ity 
Comparativ
e efficacy; 
pharmacoki
netics of 
ceftaroline 
fosamil in 
plasma 
Hypersensi
tivity to 
vancomyci
n, 
aztreonam 
or β-
lactams; 
requireme
nt for 
concomita
nt systemic 
antimicrob
ial therapy; 
history of 
seizures, 
excluding 
febrile 
seizure of 
childhood; 
signs or 
suspicion 
of 
meningitis 
Vancomyci
n i.v. 
15 mg/kg 
q6h or 
cefazolin 
i.v. 
75 mg/kg/d
ay divided 
q8h ± aztre
onam i.v. 
30 mg/kg 
q8h 
≥6 
months
: 
ceftarol
ine 
fosamil 
i.v. 
12 mg/
kg (if 
≤33 kg 
body 
weight) 
or 
400 mg 
(if 
>33 kg 
body 
weight) 
q8h 
<6 
months
: 
8 mg/k
g q8h 
Recrui
ting 
 pts, patients; RCT, randomised controlled trial; SB, single blind; CAP, community-acquired pneumonia; CSF, cerebrospinal 
fluid; i.v., intravenous; q12h, every 12 h; q8h, every 8 h; cSSTI, complicated skin and soft-tissue infection; q6h, every 6 h. 
Table options 
A PIP for treatment of cSSTI and CAP has been agreed [22]. 
3.3. Daptomycin 
Daptomycin is a cyclic lipopeptide that was approved by the FDA in 2003 for the treatment of adults with SSTIs caused by 
Gram-positive bacteria as well as S. aureusbacteraemia or right-sided endocarditis. It is inactivated by pulmonary surfactants 
and therefore should not be used for non-haematogenous pneumonia [23] and [24]. 
Daptomycin binds to the bacterial cell membrane in a calcium-dependent manner, causing rapid membrane depolarisation and 
bacterial death. It has selective activity against Gram-positive bacteria, including glycopeptide-resistant enterococci, MRSA, 
MRSE, streptococci and corynebacteria. In adults, daptomycin is given intravenously at 4 mg/kg or 6 mg/kg once daily, 
respectively, for SSTIs and S. aureusbacteraemia/endocarditis. Safety and tolerability of higher dosages have been reported 
both in adults and children [25], [26] and [27]. Daptomycin is generally well tolerated. As its most relevant side effect is 
muscular toxicity, regular monitoring of creatine kinase levels is recommended [28]. A warning that daptomycin could cause 
life-threatening eosinophilic pneumonia has recently been issued [29]. 
The experience of daptomycin in children is very limited and the paediatric dosing regimen remains to be 
determined [30], [31], [32], [33], [34] and [35]. According to the latest Infectious Diseases Society of America (IDSA) 
guidelines on the management of MRSA infections, daptomycin should be administered at 6–10 mg/kg every 24 h in children 
with bacteraemia, osteomyelitis and septic arthritis [36]. 
The pharmacokinetic (PK) profile, efficacy and safety of daptomycin in infants and children are under evaluation in several 
trials. Among these, only two are recruiting children in the EU. One study aims at characterising the peak concentration of 
daptomycin in cerebrospinal fluid of children aged 3 months to 16 years with acute Gram-positive meningitis (Table 4); 
daptomycin will be given as single-dose add-on therapy [37]. The second study will describe the safety and efficacy of 
daptomycin versus standard of care in children aged 2–17 years with S. aureus bacteraemia [38]. 
Table 4. 
European clinical trials on daptomycin (DAP) involving paediatric patients. 
Study no. 
Stu
dy 
typ
e 
Locat
ions 
No. of 
pts Age 
Type of 
infection 
Primary 
endpoint 
Second
ary 
endpoi
nt 
Main 
exclusion 
criteria 
Daptom
ycin 
dose/du
ration 
Compar
ators Status 
NCT01522
105[37] 
OL
, 
SG
A, 
ph
ase 
1 
Euro
pe 
5 
(estim
ated) 
3 
mo
nths 
to 
16 
year
s 
Gram-
positive 
meningitis 
Character
isation of 
peak 
concentra
tion of 
DAP in 
the CSF 
Evaluat
e 
possibl
e side 
effects 
of DAP 
Gram-
negative 
bacteria in 
the CSF; 
renal 
impairmen
t; CK level 
>2× upper 
age-
related 
norm or 
muscular 
disease/we
akness; 
allergy or 
hypersensi
tivity to 
DAP; 
known 
significant 
chronic 
One i.v. 
dose 
(3–24 
months, 
6 mg/k
g; 2–6 
years, 
10 mg/
kg; 7–
11 
years, 
8 mg/k
g; 12–
16 
years, 
6 mg/k
g) 
given 
24 h 
after 
first 
None Recru
iting 
Study no. 
Stu
dy 
typ
e 
Locat
ions 
No. of 
pts Age 
Type of 
infection 
Primary 
endpoint 
Second
ary 
endpoi
nt 
Main 
exclusion 
criteria 
Daptom
ycin 
dose/du
ration 
Compar
ators Status 
diseases; 
underlying 
neurologic
al disease 
with 
disruption 
of blood–
brain 
barrier; 
epilepsy, 
peripheral 
neuropath
y, 
Guillain–
Barré 
syndrome 
ceftriax
one 
dose 
NCT01728
376[38] 
RC
T, 
SB
, 
ph
ase 
4 
USA, 
Euro
pe, 
South 
Amer
ica, 
Asia 
75 
(estim
ated) 
2–
17 
year
s 
Staphyloc
occus 
aureusbact
eraemia 
Compara
tive 
safety 
Compa
rative 
efficac
y 
Shock or 
hypotensio
n 
unresponsi
ve to 
standard 
therapy; 
intoleranc
DAP 
i.v. at 
7 mg/k
g (age 
12–17 
years), 
9 mg/k
g (age 
Vancom
ycin, 
semisyn
thetic 
penicilli
n, first-
generati
on 
Recru
iting 
Study no. 
Stu
dy 
typ
e 
Locat
ions 
No. of 
pts Age 
Type of 
infection 
Primary 
endpoint 
Second
ary 
endpoi
nt 
Main 
exclusion 
criteria 
Daptom
ycin 
dose/du
ration 
Compar
ators Status 
e or 
hypersensi
tivity to 
DAP; 
renal 
insufficien
cy; 
rhabdomy
olysis; or 
significant 
CK 
elevation; 
history of 
clinically 
significant 
muscular 
disease, 
nervous 
system or 
seizure 
disorder; S
. 
aureuspne
umonia, 
7–11 
years), 
12 mg/
kg 
(ages 
2–6 
years) 
cephalos
porin, 
clindam
ycin 
Study no. 
Stu
dy 
typ
e 
Locat
ions 
No. of 
pts Age 
Type of 
infection 
Primary 
endpoint 
Second
ary 
endpoi
nt 
Main 
exclusion 
criteria 
Daptom
ycin 
dose/du
ration 
Compar
ators Status 
empyema, 
meningitis 
or 
endocardit
is 
 
pts, patients; OL, open label; SGA, single group assignment; CSF, cerebrospinal fluid; CK, creatine kinase; i.v., intravenous; 
RCT, randomised controlled trial; SB, single blind. 
Table options 
At present, the lack of adequate safety data does not allow daptomycin to be routinely used in children. Potential uses in 
selected cases include right-sided endocarditis with or without bacteraemia, infection of intravascular devices, and 
osteoarticular infections caused by MRSA, MRSE and vancomycin-resistant enterococci (VRE) [39]. 
No PIP is currently agreed on daptomycin. 
3.4. Doripenem monohydrate 
Doripenem monohydrate is the most recently developed carbapenem [40] and [41]. It was approved by the EMA in 2008 for 
the treatment of nosocomial pneumonia (NP) [including ventilator-associated pneumonia (VAP)], complicated intra-abdominal 
infections (cIAIs) and complicated urinary tract infections (cUTIs) including pyelonephritis. 
When compared with imipenem/cilastatin and meropenem, doripenem had enhanced in vitro activity against P. 
aeruginosa and Acinetobacter spp. It is also active against most β-lactam-susceptible Gram-positive bacteria, Gram-negative 
bacteria (including ESBL-producing strains) and anaerobes. As with other carbapenems, it inhibits synthesis of the bacterial 
cell wall by attaching to PBPs and has no activity against Stenotrophomonas maltophilia. Adverse effects of doripenem are 
similar to those of other carbapenems [40], [41], [42], [43] and [44]. 
In phase 3 studies, doripenem was non-inferior to comparators in the treatment of NP and cIAIs [45], [46] and [47]. However, 
a recent trial evaluating its safety and efficacy in severely ill patients with VAP was terminated prematurely due to excess 
mortality and poorer clinical cure rates in the doripenem group [48]: in that study, doripenem was administered at a higher 
dose [1 g every 8 h (q8h)] and for a shorter treatment period (7 days) than currently authorised (500 mg q8h for 10–14 days) 
and was compared with 1 g q8h of imipenem/cilastatin for 10 days. Following these preliminary results, the EMA's Committee 
for Medicinal Products for Human Use (CHMP) recommended updating the prescribing information allowing higher doses 
(1 g q8h for 10–14 days) in patients with NP caused by non-fermenting Gram-negative bacteria [49]. 
PK and pharmacovigilance studies of doripenem in children have been started in Europe (Table 5). 
Table 5. 
European clinical trials on doripenem monohydrate involving paediatric patients. 
Study no. 
St
ud
y 
ty
pe 
Loca
tions 
N
o. 
o
f 
pt
s 
Ag
e 
Type 
of 
infec
tion 
Primar
y 
endpoi
nt 
Second
ary 
endpoin
t(s) 
Main 
exclusion 
criteria 
Comparator
(s) 
Doripenem 
dose/durati
on 
Statu
s 
Res
ults 
NCT013
81848, 
EudraCT 
2009-
014387-
20 [50] a
nd [51] 
Ph
as
e 
1, 
O
L 
USA
, 
Euro
pe 
4
8 
0–
12 
we
eks 
Bact
erial 
infec
tion 
PK 
study 
(doripe
nem 
concen
trations 
in 
blood 
Safety 
of 
single-
dose 
doripen
em 
Clinically 
significant 
abnormal 
physical 
examination, 
vital signs or 
laboratory 
None Single i.v. 
dose: 
5 mg/kg in 
pts <8 
weeks; 
8 mg/kg in 
Com
plete
d 
NA 
Study no. 
St
ud
y 
ty
pe 
Loca
tions 
N
o. 
o
f 
pt
s 
Ag
e 
Type 
of 
infec
tion 
Primar
y 
endpoi
nt 
Second
ary 
endpoin
t(s) 
Main 
exclusion 
criteria 
Comparator
(s) 
Doripenem 
dose/durati
on 
Statu
s 
Res
ults 
sample
s) 
testing at 
screening 
pts ≥8 
weeks 
NCT011
10421, 
EudraCT 
2009-
016069-
27 [52] a
nd [53] 
Ph
as
e 
3, 
R
C
T, 
D
B 
Sout
h 
and 
Cent
ral 
Ame
rica, 
USA
, 
Euro
pe, 
Asia 
1
4
0 
3 
mo
nth
s to 
18 
yea
rs 
CAP Compa
rative 
safety 
Clinical 
cure at 
TOC 
and 
EOT; 
relapse 
at 
LTFU; 
populati
on PK 
analysis 
Suspected or 
proven study 
drug-resistant 
organisms 
(e.g. Staphylo
coccus 
aureus, Steno
trophomonas, 
etc.); 
immunosuppr
ession (ANC 
<500 
cells/μL); 
epilepsy 
Cefepime 
i.v. 
(50 mg/kg 
up to 
2 g/dose 
q8h) for ≥3 
days, 
followed by 
PO 
amoxicillin/
clavulanate 
potassium 
or other PO 
antibiotics 
(total 10–14 
days) 
20 mg/kg 
i.v. up to 
500 mg/dos
e q8h for 
≥3 days, 
followed by 
PO 
amoxicillin/
clavulanate 
potassium 
or 
alternative 
PO 
antibiotic 
therapy 
(total 10–14 
days) 
Susp
ende
d 
NA 
Study no. 
St
ud
y 
ty
pe 
Loca
tions 
N
o. 
o
f 
pt
s 
Ag
e 
Type 
of 
infec
tion 
Primar
y 
endpoi
nt 
Second
ary 
endpoin
t(s) 
Main 
exclusion 
criteria 
Comparator
(s) 
Doripenem 
dose/durati
on 
Statu
s 
Res
ults 
NCT011
10408, 
EudraCT 
2009-
015953-
18 [54] a
nd [55] 
Ph
as
e 
3, 
R
C
T, 
D
B 
USA
, 
Euro
pe, 
Asia
, 
Sout
h 
Ame
rica, 
Afri
ca 
1
4
0 
3 
mo
nth
s to 
18 
yea
rs 
cUTI Compa
rative 
safety 
Clinical 
cure 
and 
microbi
ological 
respons
e at 
TOC 
and 
LTFU; 
clinical 
improv
ement 
and 
microbi
ological 
respons
e at 
EOT; 
populati
on PK 
analysis 
Concomitant 
infections; 
diagnosis of 
intractable 
UTI, 
permanent 
urinary 
catheter, 
abscesses; 
suspected or 
proven study 
drug-resistant 
organisms; 
ANC <500 
cells/μL; 
epilepsy 
Cefepime 
i.v. 
(50 mg/kg 
up to 
2 g/dose 
q8h) for 3–
14 days. 
Pts may be 
discharged 
with PO 
antibiotic 
therapy 
20 mg/kg 
i.v. up to 
500 mg/dos
e q8h for 3–
14 days. 
Pts may be 
discharged 
with PO 
antibiotic 
therapy 
Recr
uitin
g 
NA 
Study no. 
St
ud
y 
ty
pe 
Loca
tions 
N
o. 
o
f 
pt
s 
Ag
e 
Type 
of 
infec
tion 
Primar
y 
endpoi
nt 
Second
ary 
endpoin
t(s) 
Main 
exclusion 
criteria 
Comparator
(s) 
Doripenem 
dose/durati
on 
Statu
s 
Res
ults 
NCT011
10382, 
EudraCT 
2009-
015864-
32 [56] a
nd [57] 
Ph
as
e 
3, 
R
C
T, 
D
B 
USA
, 
Euro
pe, 
Sout
h 
Ame
rica 
1
4
0 
3 
mo
nth
s to 
18 
yea
rs 
cIAI Compa
rative 
safety 
Clinical 
cure 
and 
microbi
ological 
respons
e at 
TOC 
and 
LTFU; 
clinical 
improv
ement 
at EOT; 
populati
on PK 
analysis 
Concomitant 
infections; 
abdominal 
wall abscess; 
suspected or 
proven study 
drug-resistant 
organisms; 
ANC <500 
cells/μL; 
epilepsy 
Meropenem 
20 mg/kg 
i.v. up to 
1 g/dose 
q8h for 3–
14 days. 
i.v. drugs 
may be 
switched to 
a PO 
antibiotic to 
complete 
the 5–14-
day course 
of treatment 
20 mg/kg 
i.v. up to 
500 mg/dos
e q8h for 3–
14 days. 
i.v. drugs 
may be 
switched to 
an oral 
antibiotic to 
complete 
the 5–14-
day course 
of treatment 
Recr
uitin
g 
NA 
NCT013
66651[58
] 
Ph
as
e 
1, 
Euro
pe 
1
0 
0–1 
yea
r 
Meni
ngitis 
PK 
study 
(doripe
nem 
concen
Safety 
of 
doripen
em 
Any 
condition that 
may interfere 
with the 
assessment, 
None Pts <12 
weeks, 
10 mg/kg 
i.v. q8h for 
5 doses; pts 
Recr
uitin
g 
NA 
Study no. 
St
ud
y 
ty
pe 
Loca
tions 
N
o. 
o
f 
pt
s 
Ag
e 
Type 
of 
infec
tion 
Primar
y 
endpoi
nt 
Second
ary 
endpoin
t(s) 
Main 
exclusion 
criteria 
Comparator
(s) 
Doripenem 
dose/durati
on 
Statu
s 
Res
ults 
O
L 
trations 
in CSF 
and 
plasma
) 
according to 
investigator 
≥12 weeks 
to <1 year, 
30 mg/kg 
i.v. q8h for 
5 doses 
pts, patients; OL, open label; PK, pharmacokinetic; i.v., intravenous; NA, not available; RCT, randomised controlled trial; DB, 
double blind; CAP, community-acquired pneumonia; TOC, test of cure; EOT, end of i.v. therapy; LTFU, long-term follow-up; 
ANC, absolute neutrophil count; q8h, every 8 h; PO, per os; cUTI, complicated urinary tract infection; cIAI, complicated intra-
abdominal infection; CSF, cerebrospinal fluid. 
Table options 
The pharmacokinetics, safety and tolerability of single-dose doripenem have been studied in hospitalised neonates (both term 
and preterm) and in infants <12 weeks of age with, or at risk for, bacterial infections under treatment with other intravenous 
(i.v.) antibiotics [50] and [51]. In that study, doripenem was given as add-on therapy. The study was completed in April 2012 
but results are not available at present. One study comparing the safety and tolerability of doripenem with cefepime in children 
with bacterial pneumonia was suspended following premature discontinuation of the adult VAP study [52] and [53]. Three 
randomised controlled paediatric studies are currently ongoing. Doripenem is compared with i.v. cefepime for safety and 
efficacy in the treatment of cUTIs in children aged 3 months to 18 years; sampling for PK investigation is scheduled in 
doripenem-treated subjects [54] and [55]. A second study is evaluating doripenem versus meropenem in hospitalised children 
with cIAIs; a PK subanalysis for the doripenem group is also planned [56] and [57]. Another study plans to assess the 
penetration of doripenem (given as add-on therapy) into the cerebrospinal fluid of hospitalised children aged <1 year with 
meningitis [58]. 
Following the limited data on the safety of doripenem and its limited potential advantages over older carbapenems, its role in 
paediatrics remains to be established. Given its broad spectrum of activity, it might be useful for treating children with 
nosocomial infections or with infections caused by enteric or non-fermentative Gram-negative bacteria [41]. 
A PIP for treatment of hospital-acquired pneumonia (HAP)/VAP, cIAIs and UTIs including complicated and uncomplicated 
pyelonephritis and cases with concurrent bacteraemia has been agreed [59]. 
3.5. Ertapenem sodium 
Ertapenem is a carbapenem with broad-spectrum antibacterial activity against aerobic and anaerobic pathogens, including 
ESBL- and AmpC-producing Gram-negatives [60] and [61]. In contrast to other carbapenems, it is not active against P. 
aeruginosa and Acinetobacter baumannii. Ertapenem is approved in Europe for the treatment of adults and children aged ≥3 
months with cIAIs, CAP, diabetic foot infections and acute pelvic infection. It is also licensed for surgical-site infection 
prophylaxis in elective colorectal surgery in adults. Further indications in the USA include cSSTIs and UTIs [62]. Paediatric 
dosing is 15 mg/kg i.v. every 12 h (q12h) in children aged 3 months to 12 years (maximum 1 g/daily) and 1 g once daily in 
older children [60]. The intramuscular route has been licensed in the USA but not in Europe. The safety profile in children was 
comparable with that found in adults [60]. Use of ertapenem was associated with neutropenia, diarrhoea and mild-to-moderate 
elevation of liver function tests; seizures were identified with comparable frequency to comparators [63]. 
Arguedas et al. investigated the safety, tolerability and efficacy of ertapenem versus ceftriaxone in children aged 3 months to 
17 years with cUTIs, SSTIs or CAP (Table 6) [64] and [65]. The overall incidence of clinical adverse events (AEs) was 
comparable between the two groups. The most common drug-related AEs were diarrhoea, vomiting, infusion-site pain and 
erythema. In general, the clinical response to ertapenem was similar to that found in adults for similar infections. 
Table 6. 
European clinical trials on ertapenem sodium involving paediatric patients. 
Study no. 
St
ud
y 
ty
pe 
Locat
ions 
N
o. 
o
f 
pt
s 
Ag
e 
Typ
e of 
infe
ctio
n 
Primary 
endpoint 
Secondar
y 
endpoint(
s) 
Main 
exclusion 
criteria 
Compa
rator 
Ertape
nem 
dose/d
uration 
Statu
s 
Result
s 
NCT00451386
[64] and [65] 
Ph
as
e 
3, 
R
C
T 
Euro
pe, 
USA, 
South 
Amer
ica 
4
0
3 
3 
mo
nth
s to 
17 
yea
rs 
cUT
I, 
CA
P, 
SST
I 
Compar
ative 
safety 
(inciden
ce of 
clinical 
and 
laborato
ry drug-
related 
serious 
AEs) 
Comparat
ive 
tolerabilit
y and 
efficacy 
Infected 
burn 
wounds; 
necrotising 
fasciitis; 
osteomyeli
tis or 
septic 
arthritis; 
mechanica
l 
ventilation
; cystic 
fibrosis; 
chronic 
lung 
disease or 
empyema; 
significant 
renal 
impairmen
t 
Ceftria
xone 
13–17 
years, 
1 g i.v. 
OD; 3 
months
–12 
years, 
15 mg/
kg 
BID 
(maxi
mum 
1 g 
daily) 
for a 
mean 
of 4 
days 
Com
plete
d 
Most 
comm
on 
drug-
related 
clinica
l AEs: 
diarrh
oea 
(5.9% 
ertape
nem, 
10% 
ceftria
xone), 
infusi
on-site 
erythe
ma 
(3% 
ertape
nem, 
Study no. 
St
ud
y 
ty
pe 
Locat
ions 
N
o. 
o
f 
pt
s 
Ag
e 
Typ
e of 
infe
ctio
n 
Primary 
endpoint 
Secondar
y 
endpoint(
s) 
Main 
exclusion 
criteria 
Compa
rator 
Ertape
nem 
dose/d
uration 
Statu
s 
Result
s 
2% 
ceftria
xone), 
infusi
on-site 
pain 
(5% 
ertape
nem, 
1% 
ceftria
xone). 
Seriou
s 
drug-
related 
clinica
l AE: 
1 pt 
each. 
No 
seriou
Study no. 
St
ud
y 
ty
pe 
Locat
ions 
N
o. 
o
f 
pt
s 
Ag
e 
Typ
e of 
infe
ctio
n 
Primary 
endpoint 
Secondar
y 
endpoint(
s) 
Main 
exclusion 
criteria 
Compa
rator 
Ertape
nem 
dose/d
uration 
Statu
s 
Result
s 
s 
drug-
related 
labora
tory 
AEs. 
Overal
l 
clinica
l 
respon
se to 
ertape
nem 
simila
r to 
larger 
clinica
l trials 
in 
adults 
Study no. 
St
ud
y 
ty
pe 
Locat
ions 
N
o. 
o
f 
pt
s 
Ag
e 
Typ
e of 
infe
ctio
n 
Primary 
endpoint 
Secondar
y 
endpoint(
s) 
Main 
exclusion 
criteria 
Compa
rator 
Ertape
nem 
dose/d
uration 
Statu
s 
Result
s 
NCT01069900
, EudraCT 
2009-015578-
37 [66] and [6
7] 
R
C
T, 
D
B, 
ph
as
e 3 
Euro
pe, 
South 
Amer
ica, 
USA, 
South
/East 
Asia 
3
0
0 
3 
mo
nth
s to 
17 
yea
rs 
IAI Compar
ative 
safety 
with a 
special 
focus on 
cardiac 
and 
musculo
skeletal 
events 
Evaluatio
n of 
musculos
keletal 
AEs; 
evaluatio
n of 
electrocar
diogram 
profiles 
obtained 
on Days 
1 and 3 
pre 
treatment 
and post 
treatment
; clinical 
response 
at TOC 
and EOT; 
bacteriol
Spontaneo
us 
bacterial 
peritonitis; 
all 
pancreatic 
processes; 
early acute 
or 
suppurativ
e (non-
perforated) 
appendiciti
s; known 
severe 
immunosu
ppression; 
congenital 
or acquired 
QT 
prolongati
on; 
Moxifl
oxacin 
1 g i.v. 
OD 
(age 
13–18 
years) 
or i.v. 
15 mg 
q12h, 
max 
1 g 
daily 
(age 
<13 
years) 
for 3–
14 
days 
Recru
iting 
NA 
Study no. 
St
ud
y 
ty
pe 
Locat
ions 
N
o. 
o
f 
pt
s 
Ag
e 
Typ
e of 
infe
ctio
n 
Primary 
endpoint 
Secondar
y 
endpoint(
s) 
Main 
exclusion 
criteria 
Compa
rator 
Ertape
nem 
dose/d
uration 
Statu
s 
Result
s 
ogical 
response 
at Days 
3–5 and 
EOT 
concomita
nt 
treatment 
with QT 
prolonging 
drugs; 
history of 
tendon 
disease/dis
order 
related to 
quinolone 
treatment; 
abnormal 
musculosk
eletal 
findings at 
baseline 
pts, patients; RCT, randomised controlled trial; cUTI, complicated urinary tract infection; CAP, community-acquired 
pneumonia; SSTI, skin and soft-tissue infection; AE, adverse event; i.v., intravenous; OD, once daily; BID, twice daily; DB, 
double blind; IAI, intra-abdominal infection; TOC, test of cure; EOT, end of therapy; q12h, every 12 h; NA, not available. 
Table options 
In a separate RCT, ertapenem was the comparator drug to moxifloxacin in children aged 3 months to 17 years with 
cIAIs [66] and [67]. 
A potential advantage of ertapenem compared with other carbapenems is the spectrum of activity sparing P. 
aeruginosa: ertapenem does not adversely affect carbapenem resistance among these bacteria, and improved P. 
aeruginosa susceptibilities have been reported after years of its use [61] and [68]. Ertapenem's prolonged half-life with once-
daily dosing facilitates its use in outpatient parenteral antibiotic therapy (OPAT) for children older than 12 years. 
No PIP is currently available on ertapenem. 
3.6. Fidaxomicin 
Fidaxomicin is the first in a new class of narrow-spectrum 18-ring macrolide antibiotics. Produced by an actinomycete, it has 
selective bactericidal activity against pathogenic Clostridium difficile, with minimal effects on the normal intestinal 
microflora. Its mechanism of action consists in inhibition of bacterial RNA polymerase [69] and [70]. 
Fidaxomicin is approved in the EU and USA for the treatment of adults with C. difficile-associated diarrhoea (CDAD). In pre-
marketing studies, fidaxomicin was non-inferior to oral vancomycin in achieving clinical cure of CDAD (92.1% vs. 89.8%) 
and was associated with fewer recurrences [71]. In the USA, a study on the safety, tolerability and pharmacokinetics of 
fidaxomicin in children (6 months to 18 years) with CDAD is currently in progress [72]. In the EU, a prospective observational 
study in children has recently started (Table 7), aiming to determine the incidence and clinical outcomes of C. 
difficile infection in 60 term neonates and to investigate the feasibility of a potential interventional study [73]. 
Table 7. 
European clinical trial on fidaxomicin involving paediatric patients. 
Study no. Study type 
Locati
on 
No. of 
pts 
Ag
e 
Type 
of 
infecti
on 
Primary 
endpoints 
Seconda
ry 
endpoin
t 
Main exclusion 
criteria Status 
NCT01533844
[73] 
Observatio
nal, non- 
interventio
nal 
Europ
e 
60 
(estimat
ed) 
0–
27 
day
s 
CDAD To 
determine 
the 
feasibility 
of a 
potential 
interventio
nal study 
with 
fidaxomici
n; to 
determine 
the 
incidence 
and 
clinical 
aspects of 
CDI in 
neonates 
and 
whether a 
subgroup 
can be 
identified 
– Preterm 
neonates; 
negative Clostri
dium 
difficiletoxin 
test 
Recruiti
ng 
Study no. Study type 
Locati
on 
No. of 
pts 
Ag
e 
Type 
of 
infecti
on 
Primary 
endpoints 
Seconda
ry 
endpoin
t 
Main exclusion 
criteria Status 
where 
treatment 
with 
fidaxomici
n therapy 
might 
improve 
outcome 
pts, patients; CDAD, Clostridium difficile-associated disease; CDI, C. difficile infection. 
Table options 
A PIP for treatment of CDAD in children has been agreed [74]. 
3.7. Linezolid 
Linezolid is the first member of the oxazolidinones [75]. It exhibits a selective spectrum of activity against Gram-positive 
bacteria, including MRSA, MRSE, VRE and PRSP. Linezolid inhibits bacterial protein synthesis through blocking the 
initiation process. 
In Europe, approved indications for its use in adults are CAP, HAP and cSSTIs caused by Gram-positive bacteria. The FDA 
labelled linezolid for paediatric use in 2002 at doses of 10 mg/kg q8h in children aged 0–11 years and 10 mg/kg q12h 
(maximum 600 mg q12h) in older children. Conversely, in most European countries it remains off-label in the paediatric 
setting, although recent reports note that it is occasionally prescribed in children [76] and [77]. Neonatal dosing of linezolid has 
been poorly studied. PK data suggest that linezolid clearance is decreased in preterm and in term neonates <7 days of age; 
therefore, all neonates should be treated with 10 mg/kg q12h during their first week of life [78]. The main side effects in 
children are gastrointestinal disturbances. Peripheral and optic neuropathy and myelotoxicity seem less frequent than in adults, 
however the risk of these severe complications should be considered and careful monitoring is recommended [77]. Linezolid 
has several advantages over glycopeptides. The high and rapid tissue penetration supports its use for central nervous system or 
osteoarticular infections. The oral formulation, with excellent bioavailability, can be useful in step-down therapy and in 
outpatients. Its activity against mycobacteria justifies its potential role in treating drug-resistant tuberculosis [79]. 
Five clinical trials enrolling adults and children (aged 13–17 years) treated with linezolid have been completed in the EU 
(Table 8). In three trials, linezolid was administered to treat CAP caused by PRSP, cSSTIs and catheter-related bloodstream 
infections due to Gram-positive organisms, or febrile neutropenia in oncological patients [80], [81], [82], [83] and [84]. In all 
these studies the number of enrolled children was limited and a stratified analysis for the paediatric population was not given. 
Therefore, no definite conclusions can be drawn. For the remaining two trials, evaluating children aged 0–17 years with 
haemato-oncological disease or undergoing haematopoietic stem cell transplantation, results are not yet available. The first 
study evaluated the efficacy and safety of rescue therapy with antibiotic-lock technique with either linezolid, vancomycin or 
amikacin for the treatment of indwelling central venous catheter (CVC)-related bacteraemia in retained CVC [85]. The second 
study evaluated continuous infusion with either linezolid, vancomycin, ceftazidime or meropenem as salvage therapy of 
tunnel/pocket infections of an indwelling CVC [86]. 
Table 8. 
European clinical trials on linezolid (LNZ) involving paediatric patients. 
Study no. 
Stud
y 
type 
Loca
tions 
No. 
of 
pts 
(ITT
) Age 
Type of 
infection 
Primar
y 
endpoi
nts 
Second
ary 
endpoi
nt 
Main 
exclus
ion 
criteri
a 
Comp
arator(
s) 
Linez
olid 
dose/
durati
on 
Statu
s Results 
NCT0003
5269[80] 
Phas
e 3, 
not 
contr
Euro
pe, 
USA
229 14–
96 
years 
(mea
CAP 
by Streptoc
occus 
pneumoniae 
Microb
iologic
al 
Clinica
l 
efficac
Previo
us 
treatm
ent for 
None 600 m
g 
q12h 
i.v./P
Com
plete
d 
Clinica
l 
success
, 
Study no. 
Stud
y 
type 
Loca
tions 
No. 
of 
pts 
(ITT
) Age 
Type of 
infection 
Primar
y 
endpoi
nts 
Second
ary 
endpoi
nt 
Main 
exclus
ion 
criteri
a 
Comp
arator(
s) 
Linez
olid 
dose/
durati
on 
Statu
s Results 
olled
, OL 
, 
Asia 
n 
54.5 
years
) 
efficac
y 
y and 
safety 
>24 h 
with 
anothe
r 
antibi
otic; 
HIV-
positi
ve 
subjec
ts; 
low 
CD4 
count 
O for 
10–21 
days 
77.3%. 
Microb
iologic
al 
eradica
tion, 
84.3%. 
Main 
AEs, 
abdomi
nal 
pain 
(3.5%), 
headac
he 
(3.9%), 
diarrho
ea 
(4.4%), 
nausea 
(5.7%), 
anaemi
a 
Study no. 
Stud
y 
type 
Loca
tions 
No. 
of 
pts 
(ITT
) Age 
Type of 
infection 
Primar
y 
endpoi
nts 
Second
ary 
endpoi
nt 
Main 
exclus
ion 
criteri
a 
Comp
arator(
s) 
Linez
olid 
dose/
durati
on 
Statu
s Results 
(3.1%), 
insomn
ia 
(3.5%) 
NCT0003
7050, 
EudraCT: 
2004-
001511-
54 [81], [
82] and [8
3] 
Phas
e 3, 
RCT
, OL 
Euro
pe, 
USA
, 
Latin 
Ame
rica, 
Sout
h 
Ame
rica, 
Asia, 
Russ
ian 
Fede
ratio
n, 
Sout
h 
363 
LNZ
, 363 
com
parat
or 
LNZ, 
16–
92 
years 
(mea
n 
53.7)
; 
comp
arato
r, 
14–
94 
years 
(mea
n 
53.8 
Central 
indwelling 
catheter-
related 
cSSTI or 
bacteraemia 
by Staphylo
coccus 
aureus, 
CoNS, Ente
rococcusspp
. 
Evaluat
e 
empiric
al 
treatme
nt 
Compa
rative 
efficac
y of 
LNZ; 
inciden
ce of 
late 
metasta
tic 
sequela
e in 
patient
s 
treated 
with 
LNZ 
Tunne
lled 
cathet
er that 
cannot 
be 
remov
ed; 
endoc
arditis
; 
infecti
on of 
perma
nent 
intrav
ascula
r 
device
Vanco
mycin 
i.v. 1 g 
q12h; 
oxacill
in i.v. 
2 g 
q6h; 
diclox
acillin 
PO 
500 m
g q6h 
600 m
g 
q12h 
i.v./P
O for 
10–28 
days 
Com
plete
d 
Clinica
l 
success
: 
cSSTIs
, 
77.8% 
LNZ, 
77.9% 
compar
ator; 
bactera
emia, 
75.3% 
LNZ, 
80.8% 
compar
ator 
Microb
Study no. 
Stud
y 
type 
Loca
tions 
No. 
of 
pts 
(ITT
) Age 
Type of 
infection 
Primar
y 
endpoi
nts 
Second
ary 
endpoi
nt 
Main 
exclus
ion 
criteri
a 
Comp
arator(
s) 
Linez
olid 
dose/
durati
on 
Statu
s Results 
Afric
a 
years
) 
s; 
previo
us 
antibi
otic 
treatm
ent for 
>24 h; 
patien
ts 
with 
HIV 
and 
low 
CD4 
count 
iologic
al 
eradica
tion: 
cSSTIs
, 
89.6% 
LNZ, 
89.9% 
compar
ator; 
bactera
emia, 
86.3 5 
LNZ, 
90.5% 
compar
ator 
NCT0003
5425 [84] 
Phas
e 3, 
RCT
, DB 
Euro
pe, 
USA
, 
Latin 
61 
LNZ
, 57 
com
LNZ, 
15–
80 
years 
(mea
Suspected 
or proven 
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EudraCT: 
2006-
000595-
32 [85] 
Phas
e 2, 
not 
contr
olled
, OL 
Euro
pe 
12 <18 
years 
Central 
indwelling 
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pts, patients; ITT, intention to treat; OL, open label; CAP, community-acquired pneumonia; HIV, human immunodeficiency 
virus; q12h, every 12 h; i.v., intravenous; PO, per os; AE, adverse event; RCT, randomised controlled trial; cSSTI, complicated 
skin and soft-tissue infection; CoNS, coagulase-negative staphylococci; q6h, every 6 h; DB, double blind; CNS, central 
nervous system; NA, not available. 
Table options 
In two previously cited RCTs, linezolid is one of the comparators for ceftaroline [20] and [21]. 
No PIP is currently available on linezolid. 
3.8. Moxifloxacin 
Moxifloxacin is a fourth-generation fluoroquinolone with a rapid bactericidal effect [87]. It acts by interfering with 
topoisomerase II and IV, which are essential enzymes for the replication, transcription and repair of bacterial DNA. Its 
spectrum of activity covers Gram-positive bacteria (including S. pneumoniae and S. aureus), Gram-negative bacteria, some 
anaerobes and atypical strains. Moxifloxacin has high oral availability and rapidly distributes to extravascular spaces, with a 
strong affinity for alveolar tissue. 
Although moxifloxacin displayed a favourable safety profile in clinical trials, the EMA-approved indications have been 
recently restricted due to the increased risk of adverse hepatic reactions [88]. They include second-line therapy of acute 
bacterial sinusitis, acute exacerbations of chronic bronchitis (AECB) and CAP. Warnings have also been raised for 
spontaneous tendon ruptures, worsening of myasthenia gravis symptoms and severe skin reactions. Other serious adverse 
effects include irreversible peripheral neuropathy and QTc prolongation [89]. 
The main advantages of moxifloxacin are once-daily administration, fast bactericidal action, good tissue penetration and broad 
spectrum of activity, including mycobacteria. 
Moxifloxacin is not licensed for paediatric use, with the exception of the topical formulation, and its dosage in children is still 
to be determined. The WHO guidelines on the treatment of drug-resistant tuberculosis recommend a moxifloxacin dose of 7.5–
10 mg/kg/day (maximum 400 mg) in children [90]. In the USA, a trial is currently investigating the pharmacokinetics of 
single-dose moxifloxacin in children aged 3 months to 14 years [91]. 
Four trials on the systemic use of moxifloxacin (hydrochloride) in children are being conducted in the EU (Table 9). 
Table 9. 
European clinical trials on moxifloxacin involving paediatric patients. 
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ion, 
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loxaci
n 
dose/d
uratio
n 
Statu
s 
Resu
lts 
ve non-
infectious 
disorders 
in the 
ear(s) 
pts, patients; RCT, randomised controlled trial; DB, double blind; IAI, intra-abdominal infection; TOC, test of cure; EOT, end 
of therapy; i.v., intravenous; OD, once daily; BID, twice daily; PO, per os; AECB, acute exacerbations of chronic bronchitis; 
AE, adverse event; cSSTI, complicated skin and soft-tissue infection; NA, not available; AOM, acute otitis media. 
Table options 
A RCT is evaluating the safety and efficacy of moxifloxacin versus ertapenem in hospitalised children with cIAIs. The study is 
still recruiting participants. The safety endpoints focus on cardiac and musculoskeletal AEs [66] and [67]. 
The remaining three studies are observational phase 4 trials, but their paediatric relevance is limited as the number of enrolled 
children is not reported and no paediatric subanalysis is available. The first study enrolled outpatients aged ≥12 years under 
daily treatment with oral moxifloxacin for AECB. It aimed to determine the impact of AECB on the patient and the community 
and to evaluate the safety and efficacy of moxifloxacin in daily practice [92] and [93]. The second study evaluated patients 
aged ≥10 years with cSSTIs: moxifloxacin under daily-life treatment conditions appeared effective and the incidence of AEs 
was low [94]. The third study evaluated the potential benefits, tolerability and safety of moxifloxacin in patients with acute 
bacterial sinusitis [95]. 
Finally, a European trial is currently evaluating the safety and efficacy of topical moxifloxacin otic solution in children with 
acute otitis media with otorrhoea and tympanostomy tubes [96]. 
PIPs for treatment of pelvic inflammatory disease in female adolescents aged from 12 years to <18 years and cIAIs aged from 
3 months to <18 years have been agreed on moxifloxacin [97], [98], [99] and [100]. 
3.9. Retapamulin 
Retapamulin is a topical antibiotic belonging to the new class of pleuromutilins. It is approved by the EMA for bacterial 
superficial skin infections, such as impetigo due to meticillin-susceptible S. aureus or Streptococcus pyogenes, in patients ≥9 
months of age. Retapamulin inhibits bacterial protein synthesis by interacting at a site on the 50S subunit of the bacterial 
ribosome through a unique mechanism. Systemic exposure following topical application through intact skin is low. The most 
common adverse reaction is irritation at the application site [101] and [102]. 
Retapamulin ointment was superior to placebo in adults and children with primary impetigo (Table 10). Pruritus at the 
application site was the most common AE (6%) [103] and [104]. Retapamulin and sodium fusidate had comparable clinical 
and bacteriological efficacy in the treatment of impetigo in adults and children aged ≥9 months; both drugs were well 
tolerated [105], [106] and [107]. The pharmacokinetics of retapamulin has been evaluated in 86 children (2–24 months) with 
secondarily infected traumatic lesions, dermatoses or impetigo. The study has been completed but the results have not been 
published [108] and [109]. A pharmacovigilance study will monitor the prescriptions of retapamulin across the EU in infants 
<9 months of age [110]. 
Table 10. 
European clinical trials on topical retapamulin involving paediatric patients. 
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recei
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secon
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recru
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pts, patients; RCT, randomised controlled trial; DB, double blind; EOT, end of treatment; FU, follow-up; BID, twice daily; SB, 
single blind; TID, three times daily; PPP, per-protocol population; ITT, intention-to-treat, OL, open label; NA, not available. 
Table options 
No PIP is available on retapamulin. 
3.10. Telithromycin 
Telithromycin is a semisynthetic erythromycin derivative and the first member of the ketolides. It was approved in Europe in 
2001 and in the USA in 2004. It acts through inhibition of bacterial protein synthesis through binding to the bacterial ribosome 
with higher affinity than erythromycin [111] and [112]. Following oral administration, telithromycin is rapidly absorbed and 
diffused into tissues and phagocytes. Telithromycin is used to treat respiratory infections as it is effective against macrolide-
resistant S. pneumoniae [113]. In Europe it is marketed for the treatment of adults with mild-to-moderate CAP, AECB, acute 
sinusitis and tonsillitis/pharyngitis caused by Group A β-haemolytic streptococci (GAS). It is also licensed at 25 mg/kg once 
daily in children aged 12–18 years with GAS tonsillitis/pharyngitis when β-lactams are not appropriate [114]. 
The most common side effects are gastrointestinal symptoms. Prolonged QTc intervals may also be observed. Recently, 
serious safety concerns have been raised regarding risks for severe liver toxicity, visual disturbances, transient loss of 
consciousness and exacerbations of myasthenia gravis: indeed, part of the telithromycin molecule acts as an antagonist of 
cholinergic receptors of muscles, eye and liver. For safety reasons, in 2007 the FDA revised the labelling removing two 
indications (acute bacterial sinusitis and AECB), whilst the EMA has recommended to restrict the use of telithromycin to the 
treatment of bronchitis, sinusitis and tonsillitis/pharyngitis caused by bacterial strains that are resistant to or cannot be treated 
with β-lactams or macrolides [115] and [116]. Following the benefit/risk evaluation by the CHMP, the marketing authorisation 
holder decided to stop the paediatric development programme [117]. Therefore, three studies investigating infants and children 
with acute otitis media were terminated in Europe (Table 11) and no PIP has been issued [118], [119] and [120]. 
Table 11. 
European clinical trials on telithromycin involving paediatric patients. 
Study no. 
Stu
dy 
typ
e 
Locat
ions 
N
o. 
of 
pt
s, Age 
Type 
of 
infecti
on 
Primary 
endpoin
t 
Secondar
y 
endpoint(
s) 
Exclusion 
criteria 
Compar
ator(s) 
Telithro
mycin 
dose/dur
ation 
Comme
nts 
NCT001748
11[118] 
RC
T, 
DB
, 
pha
se 
3 
South 
Amer
ica, 
Europ
e, 
Asia, 
USA 
6
3
9 
6–
59 
mon
ths 
AOM Clinical 
cure at 
EOT 
and 
TOC 
visit 
Time to 
symptom 
resolution
; clinical 
cure by 
causative 
pathogen; 
bacteriolo
gical 
eradicatio
n at 
comparati
ve safety; 
PK 
substudy; 
health 
resource 
utilisation 
and 
impact on 
usual 
activities 
Uncertain 
AOM not 
needing 
antibiotics; 
otorrhoea 
or 
tympanosto
my tubes; 
congenital 
abnormaliti
es; 
congenital 
prolonged 
QT 
syndrome, 
treatment 
with agents 
interfering 
with QT 
prolongatio
n; 
uncorrected 
hypokalae
Cefuroxi
me 
15 mg/k
g BID 
for 10 
days 
(PO) 
25 mg/k
g OD 
for 5–10 
days 
(PO) 
Study 
was 
terminat
ed 
before 
enrolme
nt was 
complet
ed (no 
definite 
conclusi
ons on 
efficacy 
availabl
e). 
Cure 
rate: 
telithro
mycin 
90.0%, 
cefuroxi
me 
92.7% 
Study no. 
Stu
dy 
typ
e 
Locat
ions 
N
o. 
of 
pt
s, Age 
Type 
of 
infecti
on 
Primary 
endpoin
t 
Secondar
y 
endpoint(
s) 
Exclusion 
criteria 
Compar
ator(s) 
Telithro
mycin 
dose/dur
ation 
Comme
nts 
mia, 
hypomagne
saemia, 
bradycardia
; 
myasthenia 
gravis; 
known 
impaired 
renal 
function 
NCT003150
03[119] 
RC
T, 
DB
, 
pha
se 
3 
South 
Amer
ica, 
Europ
e, 
Israel, 
USA 
3
2
1 
6 
mon
ths 
to 6 
year
s 
Suppur
ative 
AOM 
Time to 
sympto
m 
resoluti
on and 
clinical 
cure at 
the 
TOC 
visit 
Safety Mild-to-
moderate 
symptoms 
and signs of 
AOM; 
otorrhoea 
or 
tympanosto
my tube; 
congenital 
long QT 
syndrome; 
Azithro
mycin 
oral 
suspensi
on 
10 mg/k
g OD on 
Day 1, 
followed 
by 
5 mg/kg 
OD on 
25 mg/k
g OD 
for 5 
days 
(PO) 
Because 
of early 
terminat
ion of 
the 
study 
and 
limited 
data, no 
definite 
efficacy 
conclusi
Study no. 
Stu
dy 
typ
e 
Locat
ions 
N
o. 
of 
pt
s, Age 
Type 
of 
infecti
on 
Primary 
endpoin
t 
Secondar
y 
endpoint(
s) 
Exclusion 
criteria 
Compar
ator(s) 
Telithro
mycin 
dose/dur
ation 
Comme
nts 
known or 
suspected 
uncorrected 
hypokalae
mia, 
hypomagne
saemia, 
bradycardia
; 
myasthenia 
gravis; 
known 
impaired 
renal 
function; 
congenital 
abnormaliti
es; 
immunodef
iciency; 
hypersensiti
vity to 
macrolides 
Days 2–
5, max. 
500 mg 
on Day 
1 and 
250 mg/
day from 
Days 2–
5 
ons can 
be 
drawn. 
Clinical 
cure 
rate: 
telithro
mycin 
78.5%, 
azithro
mycin 
82.7%. 
Median 
time to 
sympto
m 
resolutio
n (ITT 
populati
on): 3.0 
days 
telithro
mycin; 
Study no. 
Stu
dy 
typ
e 
Locat
ions 
N
o. 
of 
pt
s, Age 
Type 
of 
infecti
on 
Primary 
endpoin
t 
Secondar
y 
endpoint(
s) 
Exclusion 
criteria 
Compar
ator(s) 
Telithro
mycin 
dose/dur
ation 
Comme
nts 
2.75 
days 
azithro
mycin 
EudraCT: 
2004-
000738-
34 [120] 
RC
T, 
DB 
Europ
e and 
non-
EU 
states 
9
0
0 
6–
59 
mon
ths 
AOM Non-
inferiori
ty of 
telithro
mycin 
vs. 
cefuroxi
me 
axetil 
Comparat
ive 
efficacy; 
safety of 
telithromy
cin; 
prevalenc
e of 
nasophary
ngeal 
carriage 
of Strepto
coccus 
pneumoni
ae; 
plasma 
telithromy
cin 
concentrat
Otorrhoea 
or 
tympanosto
my tube; 
otitis 
externa; 
chronic 
diseases; 
congenital 
prolonged 
QT 
syndrome; 
myasthenia 
gravis; 
impaired 
renal 
function, 
hypokalae
mia, 
Cefuroxi
me 
axetil 
15 mg/k
g BID 
for 10 
days 
25 mg/k
g OD 
for 5–10 
days 
Prematu
rely 
ended 
Study no. 
Stu
dy 
typ
e 
Locat
ions 
N
o. 
of 
pt
s, Age 
Type 
of 
infecti
on 
Primary 
endpoin
t 
Secondar
y 
endpoint(
s) 
Exclusion 
criteria 
Compar
ator(s) 
Telithro
mycin 
dose/dur
ation 
Comme
nts 
ions in a 
subset of 
subjects; 
health 
resource 
utilisation 
and 
impact on 
usual 
activities 
of 
parents/le
gally 
authorised 
representa
tives 
hypomagne
saemia, 
bradycardia 
pts, patients; RCT, randomised controlled trial; DB, double blind; AOM, acute otitis media; EOT, end of treatment; TOC, test 
of cure; PK, pharmacokinetic; BID, twice daily; PO, per os; OD, once daily; ITT, intention-to-treat; EU, European Union. 
Table options 
3.11. Tigecycline 
Tigecycline is the first member of the glycylcyclines. It is structurally similar to tetracyclines and acts as a protein synthesis 
inhibitor by binding to the 30S ribosomal subunit of bacteria [121] and [122]. Its bacteriostatic activity is maintained in the 
presence of several resistance mechanisms that affect other antibiotics and it covers a variety of Gram-positive and Gram-
negative bacteria (including MRSA, S. maltophilia, A. baumannii and multidrug-resistant Enterobacteriaceae), anaerobes and 
atypical bacteria. It is not active against P. aeruginosa, Morganella or Providencia spp.[121] and [122]. 
Tigecycline was given a fast-track approval by the FDA for the treatment of cSSTIs, cIAIs and CAP. It was authorised in the 
EU in 2006 for adults with cSSTIs (excluding diabetic foot infections) and cIAIs; a variation application to include CAP in 
licensed indications was withdrawn in 2008. 
Tigecycline has similar side effects to the tetracyclines, such as diarrhoea, nausea and vomiting. It may also cause 
photosensitivity, pseudotumour cerebri and pancreatitis [121], [122] and [123]. Its use is to be avoided in young children and 
during pregnancy owing to its effects on teeth and bone. Recently, a warning regarding increased mortality risk associated with 
tigecycline use has been issued [124] and [125]. A recent meta-analysis of RCTs of tigecycline documented that septic shock 
and superinfections were significantly more frequent in patients treated with tigecycline than with comparators. The CHMP 
has recommended to restrict tigecycline use to only when other suitable alternatives are not available and to include new 
warnings to inform prescribers of the higher mortality recorded in tigecycline trials [126]. 
Two paediatric studies on tigecycline have been conducted in Europe (Table 12). A multicentre study investigated emergency 
use of the drug in adults and children aged ≥8 years infected by resistant bacteria where other treatments had not been 
successful. The study has been completed but results for the paediatric cohort are not available [127]. A phase 2 study 
evaluated the PK profile of multiple doses of tigecycline in children aged 8–11 years with cIAIs, cSSTIs or CAP to identify an 
appropriate dose regimen (0.75, 1 or 1.25 mg/kg q12h) and to assess the safety profile and efficacy of 
tigecycline [128] and [129]. The ca. 1.2 mg/kg q12h dosage appeared the most appropriate, to be tested in phase 3 clinical 
trials. In this cohort, nausea was the most frequent AE and the overall clinical cure rate was 94%. 
Table 12. 
European clinical trials on tigecycline involving paediatric patients. 
Study no. 
Study 
type 
Locat
ions 
N
o. 
of 
pt
s 
Ag
e 
Type 
of 
infect
ion 
Primar
y 
endpoi
nt 
Secon
dary 
endpo
int(s) 
Exclusion 
criteria 
Comp
arator 
Tigecyc
line 
dose/du
ration Results 
NCT00205816[1
27] 
Non-
random
ised, 
uncontr
olled, 
OL, 
phase 3 
Euro
pe, 
USA 
2
7 
≥8 
ye
ars 
Bacte
rial 
infect
ions 
due 
to 
resist
ant 
patho
gens 
Mecha
nism 
for the 
emerg
ency 
use of 
tigecy
cline 
in 
clinica
l 
situati
ons 
Safety 
and 
effica
cy 
Expected 
survival <2 
weeks; 
hypersensit
ivity to 
tigecycline
, 
tetracyclin
es or 
related 
compound
s; 
pregnancy 
or 
breastfeedi
ng 
None Tigecyc
line, 
100 mg 
i.v. 
followe
d by 
50 mg 
q12h or 
q24h 
for 5–
90 days 
NA for the 
paediatric 
cohort 
NCT00488345[1
28] and [129] 
Rando
mised, 
OL, 
phase 2 
Euro
pe, 
South 
Afric
a, 
5
9 
8–
11 
ye
ars 
cIAI, 
cSST
I, 
CAP 
PK 
proper
ties of 
ascend
ing 
doses 
Popul
ation 
PK 
model
, 
safety, 
Endocardit
is; 
artificial 
heart valve 
or infected 
device; 
hypersensit
NA Tigecyc
line 
0.75, 1 
or 
1.25 m
g/kg 
Mean PK 
values: Cm
ax, 
1899 ng/m
L; Tmax, 
0.56 h; 
between-
Study no. 
Study 
type 
Locat
ions 
N
o. 
of 
pt
s 
Ag
e 
Type 
of 
infect
ion 
Primar
y 
endpoi
nt 
Secon
dary 
endpo
int(s) 
Exclusion 
criteria 
Comp
arator 
Tigecyc
line 
dose/du
ration Results 
Asia, 
USA 
effica
cy 
ivity to 
tigecycline 
or other 
related 
compound
s; 
immunosu
ppressed 
patients; 
serious 
infections 
(e.g. 
necrotising 
fasciitis, 
gangrene, 
empyema, 
abscess, 
etc.); 
critical 
conditions 
(sepsis and 
septic 
shock) 
i.v. for 
≥5 days 
dose AUC, 
2833 ng h/
mL; 
weight-
normalised 
clearance, 
0.503 L/h/k
g; 
and Vd,ss, 
4.88 L/kg. 
Overall 
clinical 
cure rates 
at TOC: 
94%, 76% 
and 75% in 
the 0.75, 1 
and 
1.25 mg/kg 
cohorts, 
respectivel
y. 
Nausea in 
Study no. 
Study 
type 
Locat
ions 
N
o. 
of 
pt
s 
Ag
e 
Type 
of 
infect
ion 
Primar
y 
endpoi
nt 
Secon
dary 
endpo
int(s) 
Exclusion 
criteria 
Comp
arator 
Tigecyc
line 
dose/du
ration Results 
50% of 
patients. 
PD 
simulations 
predicted 
that a 
dosage of 
ca. 
1.2 mg/kg 
q12h would 
lead to 
therapeutic 
target 
attainment 
levels of up 
to 82% for 
the target 
AUC0–
24/MIC 
ratios 
pts, patients; OL, open label; i.v., intravenous; q12h, every 12 h; q24h, every 24 h; NA, not available; cIAI, complicated intra-
abdominal infection; cSSTI, complicated skin and soft-tissue infection; CAP, community-acquired pneumonia; PK, 
pharmacokinetic; Cmax, peak concentration of drug; Tmax, time at which Cmax is observed; AUC, area under the 
concentration–time curve; Vd,ss, volume of distribution at steady state; TOC, test of cure; PD, pharmacodynamic; MIC, 
minimum inhibitory concentration. 
Table options 
A PIP has been agreed for treatment of cSSTIs and cIAIs in children aged 8–18 years [130]. 
4. Discussion 
The increasing problem of multidrug-resistant bacteria will encourage the development and hopefully subsequent approval of 
new antibiotics [2]. The need for targeted studies on antibiotics in children has been recognised as a matter of concern by the 
regulatory authorities. However, despite the recent efforts in implementing paediatric trials, the number of studies that have 
been or are being conducted in children in this area still remains strikingly low, especially in Europe. For all the different 
possible indications for the 11 antibiotics newly approved by the EMA (of which only 2 have paediatric labelling), 31 clinical 
trials enrolling children in Europe were identified. However, many of these trials were mainly focused on adults and did not 
provide a subset analysis for the older children recruited, limiting the relevance of their findings. Some studies have been 
prematurely terminated and others are active but are still not yet recruiting patients. Among paediatric-targeted studies, 18 
evaluate the safety and efficacy of new compounds, 4 are PK studies, but only 2 focus on neonates, the population in which 
dosing is likely most different from adults or older children. We could identify only one paediatric pharmacovigilance study on 
antibiotics in Europe. Nearly all studies with an agreed PIP have just started or are not yet recruiting. To our knowledge, this is 
the first comprehensive review on clinical trials conducted in the EU on antibiotics in children. Previous reports in the USA 
have documented an increase in the quantity and quality of paediatric controlled trials, demonstrating a success of the FDA 
paediatric exclusivity programme. However, it also emerged that dissemination of trial results in the literature is limited, as 
barely one-half of studies were published and determined labelling changes [131], [132] and [133]. A possible bias should also 
be taken into account in our study: unregistered trials, as well as unpublished data retained by pharmaceutical companies, may 
have led to an underestimation of available results. The new interventions and legislation introduced both in the USA and 
Europe should further promote drug evaluation in paediatrics, but the efficacy of these processes is under review. There are a 
number of steps that would improve the design of new antibiotic trials in children in Europe. These include an adequate 
knowledge of the basic epidemiology of key clinical syndromes in children (CAP, SSTI, IAI, etc.) through prospective 
observational studies. Second, a closer collaboration between clinicians and the pharmaceutical industry is necessary, 
particularly in early study design. The EMA has created a European paediatric network of research networks, investigators and 
centres with expertise in paediatric clinical studies [European Network of Paediatric Research at the European Medicines 
Agency (Enpr-EMA)], that supports high-quality studies in children and helps with fostering closer links between industry, the 
regulators, patient representatives and academic clinical trial networks [134]. 
The EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have launched a public–private 
partnership called the Innovative Medicines Initiative (IMI), aimed at improving and speeding up the drug development 
process. Combating and treatment of infectious diseases is a key research priority of the IMI programme: in May 2012, the IMI 
launched its 6th Call on the theme ‘Combating Antibiotic Resistance’ that includes ‘innovative trial design & clinical drug 
development’ [135]. It was perhaps slightly disappointing that the call did not include any specific development programme 
for children, with the call being only on clinical trials for adults. One potential model could be based on the Paediatric 
European Network for Treatment of AIDS (PENTA), established in 1991 as a collaboration between paediatric human 
immunodeficiency virus (HIV) centres in Europe, working closely with industry and the regulator to rapidly develop 
appropriate studies in children in parallel with adult HIV drug development programmes [136]. These studies are often a 
combination of PK, safety and strategic trials, rather than expensive and often not appropriate large phase 3 efficacy studies. 
PENTA has now become PENTA-ID, and can work with Pharma to develop new antimicrobials in Europe. This structured 
approach may actually speed drug development within the current regulatory framework. This level of collaboration with 
baseline observational studies, linked to planned interventional studies, is now required for antibiotics under early 
development. 
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